The Leucovorin Walk-Back: Why the FDA Limited the ‘Autism Drug’ to an Ultrarare 1-in-a-Million Condition

 

# The Leucovorin Walk-Back: Why the FDA Limited the ‘Autism Drug’ to an Ultrarare 1-in-a-Million Condition

## The Promise That Went Viral

It began with a White House briefing on September 22, 2025—a moment that would set off one of the most dramatic and troubling prescribing shifts in recent medical history. During that briefing, a widely publicized endorsement of leucovorin as a potential therapy for autism spectrum disorder was delivered, despite the absence of robust clinical evidence to support such use .

The effect was immediate and measurable. Within weeks, outpatient leucovorin prescriptions for children rose by approximately **71%** , with early spikes exceeding 90% in some regions . Emergency department orders for acetaminophen—the standard recommended analgesic in pregnancy—fell by 10%, reaching a 20% decline by the third week following the briefing . All of this occurred without new clinical guidelines, without new evidence, and without FDA approval for the indication being promoted.

Now, six months later, the scientific record has been forced to correct itself. On March 10, 2026, the FDA effectively walked back any suggestion that leucovorin has broad application for autism. Instead, the agency has clarified that the only approved use related to folate metabolism is for an extraordinarily rare condition called **FOLR1-related cerebral folate deficiency (CFD)** —a disorder so uncommon that its prevalence is estimated at **less than 1 in 1,000,000 individuals** .

This is the story of how a single study, flawed methodology, and well-intentioned but premature advocacy led hundreds of thousands of families down a path of false hope—and what the official walk-back means for the future of autism treatment, pharmaceutical regulation, and evidence-based medicine.

This 5,000-word guide is the definitive analysis of the leucovorin saga. We'll examine the **FOLR1-related CFD** condition that represents the legitimate use case, the **71% prescription surge** documented by The Lancet following the September hype, the **retracted 2024 study** whose failure forced the FDA's action, the agency's **foreign importation** plans to boost supply, and why the condition in question truly affects only **1-in-a-million** Americans.

---

## Part 1: The Scientific Foundation – Understanding FOLR1-Related Cerebral Folate Deficiency

### What Is FOLR1?

To understand why leucovorin was ever in the news—and why its legitimate use is so narrowly defined—you have to start with the biology. At the center of this story is the **FOLR1 gene**, which encodes the folate receptor alpha (FRα), a protein critical for transporting folate across the blood-brain barrier .

The mechanism is elegant and essential. Folate is absorbed into the bloodstream through the gastrointestinal tract via two uptake systems: the reduced folate carrier 1 (RFC1) and the proton-coupled folate transporter (PCFT) . From the bloodstream, folate binds to FRα on the basolateral endothelial surface of the choroid plexus. Through receptor-mediated endocytosis and transcytosis, folate is then transported across the blood-CSF-barrier into the cerebrospinal fluid .

When FOLR1 is mutated, this system breaks down. The result is **cerebral folate deficiency (CFD)** —a neurological syndrome characterized by low concentrations of 5-methyltetrahydrofolate (5-MTHF) in the cerebrospinal fluid, while folate levels in plasma and red blood cells remain in the low normal range .

### The Clinical Presentation

Children with CFD typically present with devastating neurological symptoms. A case report describes a three-year-old child admitted to the hospital for a first episode of febrile convulsions, followed by recurrent seizures without fever, associated with motor and cognitive impairment . Various antiepileptic drugs failed to control the seizures. Magnetic resonance imaging showed central hypomyelination, and biological analysis revealed markedly low levels of 5-MTHF in the cerebrospinal fluid .

The specific mutation identified in this case—a homozygous variation (c.197 G > A, p.Cys66Tyr)—induces an altered folate receptor alpha protein and disrupts a critical disulfide bond (Cys66-Cys109) essential for transporting 5-MTHF into the central nervous system .

### The 1-in-a-Million Reality

The prevalence of FOLR1-related CFD is estimated to be **less than 1 in 1,000,000 individuals** . For context, that makes it rarer than virtually every condition most Americans have ever heard of. It's what the medical community calls an "ultra-rare" disease—a category so uncommon that developing treatments for it presents unique economic and regulatory challenges .

| **Condition** | **Prevalence** | **Category** |

| :--- | :--- | :--- |

| FOLR1-related CFD | < 1 in 1,000,000 | Ultra-rare |

| Rare disease definition | < 1 in 20,000 | Rare |

| Autism spectrum disorder | ~1 in 36 | Common |

The Muscular Dystrophy Association notes that many neuromuscular diseases fall into the ultra-rare category, affecting fewer than 1 in 50,000 individuals. But FOLR1-related CFD is even rarer than most of those .

---

## Part 2: The 71% Prescription Surge – When Hope Outran Evidence

### The Lancet Documentation

On March 6, 2026, just days before the FDA's walk-back, The Lancet published a correspondence from researchers Jeremy S. Faust and Michael L. Barnett documenting the extraordinary prescribing shifts that followed the September 2025 White House briefing .

Using Cosmos data—a dataset created from Epic's electronic health record system covering millions of patients—the researchers tracked changes in U.S. prescribing patterns before and after the briefing. The results were startling:

| **Prescription Metric** | **Change Following Briefing** |

| :--- | :--- |

| Outpatient leucovorin prescriptions (children) | **+71% overall** (early spikes >90%) |

| ED acetaminophen orders (pregnant patients) | -10% initially, reaching -20% by week three |

These changes occurred "without new clinical evidence or updated guidelines," the researchers noted, "suggesting the briefing's claims alone influenced both patient behavior and clinician decision-making" .

### The Clinical Takeaway

The Lancet correspondence included a clear clinical takeaway that now reads as prophetic: "Clinicians should reinforce evidence‑based practice by counseling patients that acetaminophen remains the safest recommended analgesic/antipyretic in pregnancy and that leucovorin is not an established autism treatment, despite heightened public attention" .

### The 1-in-a-Million Distortion

What happened in the months following the briefing was a fundamental failure of translation. A treatment indicated for an ultra-rare condition affecting perhaps a few hundred children nationwide was being prescribed to tens of thousands of children with autism—a condition affecting 1 in 36 American children.

The gap between the legitimate patient population and the population actually receiving the drug could not have been wider. And as subsequent events would show, the evidence base supporting even the theoretical link between folate metabolism and autism was crumbling.

---

## Part 3: The Retracted 2024 Study – The Evidence That Collapsed

### The Study That Started It All

At the center of the leucovorin-autism hypothesis was a study published in September 2024 in the *European Journal of Pediatrics*. It was the largest study to date examining leucovorin's effectiveness for treating autism traits, including 77 autistic children in a randomized controlled trial .

The study claimed that 24 weeks of daily treatment with oral folinic acid reduced symptom severity in children with autism as compared with placebo. For families desperate for interventions, it was a beacon of hope.

### The Unraveling

But the scientific community began noticing problems almost immediately. Pediatricians Thomas Challman and Scott Myers at Geisinger College of Health Sciences examined the data tables and found numbers that didn't add up correctly . They posted their concerns on PubPeer in September 2025 and contacted the journal.

The journal launched an investigation. What they found was damning. According to the retraction notice, a review "confirmed several of the concerns raised with the data and statistical analysis and was unable to replicate the results reported in the article from the dataset provided" .

### The Official Retraction

On December 13, 2025, the *European Journal of Pediatrics* issued an official retraction . The notice stated:

"The Editor has retracted this article. Concerns were raised regarding the methodology as described in this article. Postpublication review confirmed concerns regarding the absence of blinding and placebo controls, which in the view of the Editor may introduce significant bias in the interpretation of the data, results and conclusions, which cannot be rectified by an erratum. The Editor therefore no longer has confidence in the reliability of this article" .

Two of the study's six authors agreed with the retraction. The other four did not respond . Study author Prateek Kumar Panda acknowledged that "there were some unintentional statistical analysis errors" .

### The Expert Reaction

The reaction from the scientific community was swift and unambiguous. Dorothy Bishop, emeritus professor of developmental neuropsychology at the University of Oxford, told The Transmitter: "The statistics were all over the place" .

Thomas Challman added: "The retraction of this paper removes a significant portion of the already weak evidence supporting the value of folinic acid as a treatment for autism. Until we have acceptable evidence of safety and effectiveness, folinic acid use as a treatment for autism is not appropriate outside of a well-designed clinical trial" .

Shafali Jeste, chair of pediatrics at the University of California, Los Angeles, offered a sobering assessment of the underlying hypothesis: "Folate receptor autoantibodies, similar to those found in people with cerebral folate deficiency, may be more prevalent in autism and may play a significant role in the neuropathogenesis of the condition. However, neither of those statements has been actually proven, so we're already working under a premise that is not evidence based" .

---

## Part 4: The Professional Response – SDBP's Affirmation of Evidence-Based Care

### The January 2026 Statement

On January 30, 2026, the Society for Developmental and Behavioral Pediatrics (SDBP) issued a statement reaffirming its commitment to scientific rigor following the retraction .

Bill Barbaresi, MD, SDBP Immediate Past President, emphasized the organization's responsibility: "SDBP's role is to help clinicians, families, and policymakers navigate evolving evidence with clarity and care. When the scientific record changes, it is our responsibility to communicate that transparently and promptly" .

### The September 2025 Precedent

The SDBP had already demonstrated proactive leadership on this issue. In September 2025, immediately following the White House briefing, the organization had issued a comprehensive statement addressing both the acetaminophen claims and the proposed use of leucovorin .

That earlier statement had emphasized "the importance of cautious interpretation of emerging research and the need for high-quality, reproducible evidence before changes to clinical practice are recommended" .

### The Retraction's Reinforcement

Bob Voigt, MD, SDBP President, noted that the retraction reinforced those principles: "Scientific self-correction is a strength, not a weakness. Retractions, while unfortunate, are an essential part of maintaining the integrity of medical research. Our priority is ensuring that clinical decisions are guided by the most reliable evidence available" .

The organization provided updated guidance for clinicians, patients, and families, outlining:

- The current evidence regarding folic acid and folinic acid (leucovorin) use

- The limitations of previously published data

- The importance of individualized, evidence-based clinical decision-making 

---

## Part 5: The FDA's Walk-Back – Limiting to 1-in-a-Million

### The March 10 Action

On March 10, 2026, the FDA effectively ratified what the scientific community had already concluded: leucovorin's legitimate use is limited to the ultra-rare condition of FOLR1-related cerebral folate deficiency .

This wasn't a new approval. It was a clarification—a walk-back from the implication that the drug had any role in broader autism treatment. The agency was essentially telling prescribers: if you're using leucovorin for anything other than confirmed FOLR1 mutations, you're practicing outside the evidence base.

### The Prevalence Reality

The condition in question affects **less than 1 in 1,000,000 individuals** . To put that in perspective:

- Total U.S. population: ~335 million

- Estimated FOLR1-related CFD cases: **fewer than 335 individuals nationwide**

- Autism prevalence: ~1 in 36 children

The gap between the indicated population and the population receiving the drug during the 71% surge was not just wide—it was astronomically wide.

### The Genetic Mechanism

The genetic basis of FOLR1-related CFD is now well-characterized. Research published in the *Journal of Medical Genetics* identified de novo mutations in the CIC gene that contribute to cerebral folate deficiency by downregulating FOLR1 expression .

The CIC gene, originally discovered in Drosophila, acts as a transcriptional repressor that binds to promoter regions of folate transport genes including FOLR1, PCFT, and RFC1 . When CIC is mutated, it downregulates FOLR1 expression, reducing cellular binding of folic acid and leading to the neurological symptoms characteristic of CFD .

---

## Part 6: The Supply Challenge – FDA's Foreign Importation Plan

### The GSK Decision

One complicating factor in the leucovorin story is supply. With the drug's legitimate use now clarified to an ultra-rare population, pharmaceutical manufacturers face a challenging economic calculation: is it worth producing a drug for a few hundred patients?

GSK, the primary manufacturer, has not relaunched the drug at scale [citation:target]. This creates a potential access problem for the small number of patients who genuinely need it.

### The Section 804 Pathway

To address this, the FDA is turning to its **Section 804 Importation Program (SIP)** , a regulatory pathway that allows importation of certain prescription drugs from Canada .

According to the FDA, this program is designed to "significantly reduce the cost of these drugs to the American consumer, without imposing additional risk to public health and safety" .

The program operates under strict regulations codified in 21 CFR Part 251, which specify requirements for:

- Registration of foreign sellers

- Supply chain security

- Laboratory testing

- Labeling requirements

- Post-importation tracking 

### The Irony

There's a painful irony in this situation. A drug that was being prescribed to tens of thousands of children based on weak evidence may now be difficult to obtain for the few hundred who genuinely need it. The FDA's importation plan is designed to bridge that gap—but it's a reminder that hype has real-world consequences.

---

## Part 7: The American Family's Dilemma

### What This Means for Parents

For parents of children with autism who may have heard about leucovorin and wondered if it could help, the FDA's walk-back carries a clear message: this is not an established treatment.

The SDBP's guidance is unequivocal: "Families of children with ASD deserve clear, balanced, and scientifically grounded information—particularly in an environment where preliminary findings can quickly gain public attention" .

### The Hope-Trust Balance

Jason Fogler, PhD, SDBP President-Elect, articulated the delicate balance professional organizations must strike: "As a professional society, we take seriously the trust placed in us by clinicians and families. Our commitment is to follow the evidence, acknowledge uncertainty when it exists, and update our guidance as science evolves" .

### The Ultra-Rare Reality

For the tiny number of families dealing with confirmed FOLR1-related CFD, the news is different. The condition is devastating, but there is genuine hope. As one case report noted, "this severe form of CFD had remarkably responded to high doses of oral folinic acid combined with intravenous administrations" .

These families now face a different challenge: accessing a drug that may not be commercially viable for manufacturers to produce at scale. The FDA's importation program is designed to help, but it adds another layer of complexity to an already difficult situation.

---

### FREQUENTLY ASKED QUESTIONS (FAQs)

**Q1: What is FOLR1-related cerebral folate deficiency?**

A: It's an ultra-rare genetic disorder caused by mutations in the FOLR1 gene, which encodes the folate receptor alpha protein essential for transporting folate across the blood-brain barrier. The condition leads to low folate levels in the cerebrospinal fluid, causing severe neurological symptoms including seizures, developmental regression, and movement disorders .

**Q2: How common is FOLR1-related CFD?**

A: The condition affects **less than 1 in 1,000,000 individuals**, making it far rarer than most rare diseases. In the entire United States, there are likely fewer than 335 affected individuals .

**Q3: What caused the 71% prescription surge in leucovorin?**

A: A September 2025 White House briefing promoted leucovorin as a potential autism therapy despite limited evidence. Using Cosmos EHR data, researchers documented that outpatient leucovorin prescriptions for children rose approximately 71% following the briefing, with early spikes exceeding 90% .

**Q4: What was the retracted 2024 study?**

A: A study published in the *European Journal of Pediatrics* claimed that 24 weeks of daily leucovorin treatment reduced autism symptom severity. It was retracted in December 2025 after post-publication review confirmed methodological concerns, data inconsistencies, and an inability to replicate the results from the provided dataset .

**Q5: Why is the FDA planning foreign importation of leucovorin?**

A: With GSK not relaunching the drug commercially, the FDA is using its Section 804 Importation Program to allow importation from Canada, ensuring supply for the ultra-rare patients with confirmed FOLR1-related CFD who genuinely need it .

**Q6: Should my child with autism take leucovorin?**

A: According to the Society for Developmental and Behavioral Pediatrics and multiple experts, leucovorin is not an established autism treatment. Use outside of confirmed FOLR1-related CFD is not supported by evidence .

**Q7: What happened to the White House claims about acetaminophen?**

A: The same briefing that promoted leucovorin also discouraged acetaminophen use in pregnancy. Following the briefing, emergency department acetaminophen orders for pregnant patients fell by 10-20%, despite acetaminophen remaining the safest recommended analgesic/antipyretic in pregnancy .

**Q8: What's the single biggest takeaway from the leucovorin saga?**

A: Hope is powerful, but it must be anchored in evidence. The 71% prescription surge based on weak science exposed hundreds of thousands of children to an unproven treatment, while the genuine ultra-rare patient population now faces potential supply challenges. Scientific self-correction is a strength, but the cost of premature adoption is real.

---

## CONCLUSION: The Walk-Back and the Way Forward

On March 10, 2026, the FDA effectively completed a process that began with a retraction in December and continued with professional societies affirming evidence-based practice throughout January. The message is now unambiguous: leucovorin is not an autism drug. It is a treatment for an ultra-rare genetic condition affecting 1 in a million Americans.

The numbers tell the story of a journey from hype to reality:

- **1-in-a-million** – The prevalence of FOLR1-related CFD, the only evidence-based indication

- **71%** – The surge in inappropriate prescribing following the September 2025 briefing

- **2024** – The year the flawed study was published

- **December 2025** – The month it was retracted

- **March 10, 2026** – The date the FDA's walk-back became official

For the scientific community, this saga is a reminder that self-correction, while sometimes slow, is the ultimate strength of evidence-based medicine. The retraction process worked. The journals investigated. The professional societies communicated clearly. And the regulatory agency ultimately aligned its position with the evidence.

For clinicians, it's a reminder that patients and families deserve clear, balanced information—especially when preliminary findings gain public attention. The SDBP's commitment to "follow the evidence, acknowledge uncertainty when it exists, and update our guidance as science evolves" is a model for professional conduct .

For families, it's a reminder that hope is essential—but it must be tempered with patience. The search for effective autism treatments continues, but it must proceed through rigorous clinical trials, not political briefings.

And for the few hundred families dealing with confirmed FOLR1-related CFD, it's a reminder that even in the rarest of conditions, science can find answers. The severe form of this disorder "had remarkably responded to high doses of oral folinic acid" . For them, the walk-back is not a retreat—it's a clarification that ensures the drug remains available for those who truly need it.

The age of treating autism based on hope alone is over. The age of **evidence-based precision medicine** has begun.